Zai Lab (ZLABN) Stock Price & Analysis
ZLABN Stock Chart & Stats
- Day’s Range
- MXN 810.00 - MXN 810.00
- 52-Week Range
- MXN 810.00 - MXN 810.00
- Previous Close
- MXN 810.00
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- MXN 51.95B
- Enterprise Value
- MXN 1.66B
- Total Cash (Recent Filing)
- MXN 617.52M
- Total Debt (Recent Filing)
- MXN 254.58M
- Price to Earnings (P/E)
- ―
- Beta
- -0.94
- Next Earnings
- Nov 05, 2026 (Est.)
- EPS Estimate
- -10.6
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Commercial Profitability And Sequential Growth
Sequential product growth alongside commercial profitability indicates that Zai Lab is converting its portfolio into a more productive operating base. If sustained, this combination can support reinvestment in launches and clinical programs while reducing dependence on external funding over time.
Funding For Global Development
The planned capital raise provides additional resources for advancing zoci through global development without relying solely on operating cash flow. Funding directed toward a lead program can extend execution capacity and support regulatory and clinical milestones over the next several quarters.
Promising Zoci Clinical Profile
Early combination data show substantial response and disease-control signals with a reported tolerability profile, strengthening the case for zoci as a potentially important oncology backbone. The planned global Phase 3 trial creates a clear path toward testing whether these results can translate into durable commercial value.
Bears Say
Persistent Operating Losses
Zai Lab remains materially unprofitable at both operating and net-income levels, so portfolio growth has not yet translated into sustainable corporate earnings. Continued losses constrain internal funding capacity and make future profitability dependent on successful commercialization and disciplined expense management.
Ongoing Cash Burn And Equity Erosion
Negative operating and free cash flow show that the business is still consuming capital rather than self-funding its pipeline. The decline in equity over time further reflects the cost of ongoing losses, increasing the importance of financing access and successful launches to preserve strategic flexibility.
Commercial Supply And Competitive Execution Risks
Supply limitations can prevent demand from converting into reported sales, while intensifying competition raises the evidence bar for new products such as ZL-1503. Together, these issues could delay revenue scaling and require stronger execution, clinical differentiation, or additional commercial investment.
Zai Lab News
ZLABN FAQ
What was Zai Lab’s price range in the past 12 months?
What is Zai Lab’s market cap?
When is Zai Lab’s upcoming earnings report date?
How were Zai Lab’s earnings last quarter?
Is Zai Lab overvalued?
Does Zai Lab pay dividends?
What is Zai Lab’s EPS estimate?
How many shares outstanding does Zai Lab have?
What happened to Zai Lab’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Zai Lab?
What is the TipRanks Smart Score and how is it calculated?
Zai Lab Stock Smart Score
Company Description
Zai Lab
Operating primarily in Mainland China and Hong Kong, Zai Lab Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medical treatments. Their therapeutic portfolio spans oncology, autoimmune conditions, infectious diseases, and neurological disorders. Currently available products in their portfolio include Zejula, a once-daily small-molecule PARP 1/2 inhibitor; Optune, a medical device leveraging tumor treating fields; NUZYRA, an antimicrobial agent for specific acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia; and Qinlock, indicated for gastrointestinal stromal tumors. Beyond its commercial offerings, Zai Lab boasts an extensive pipeline of investigational therapies. These include Odronextamab for various B-cell lymphomas; Repotrectinib, a tyrosine kinase inhibitor targeting ROS1 and TRK pathways in both TKI-naïve and pretreated cancer patients; Margetuximab for breast and gastroesophageal cancers; Adagrasib for KRAS-G12C-mutated solid tumors like NSCLC, colorectal, and pancreatic cancers; and Bemarituzumab for gastric and gastroesophageal junction cancers. Further pipeline candidates encompass CLN-081 for EGFR exon 20 insertion NSCLC; Elzovantinib, an orally available multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab, designed to block PD-1 interactions with its ligands; ZL-2309, an orally active and selective CDC7 kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod, aimed at reducing pathogenic immunoglobulin G antibodies; ZL-1102, a human nanobody against interleukin-17A; KarXT for psychiatric and neurological conditions; ZL-2313 and ZL-2314, both investigational EGFR inhibitors targeting specific mutations; and Sulbactam/durlobactam, intended for serious infections caused by Acinetobacter. Established in 2013, Zai Lab Limited maintains its corporate headquarters in Shanghai, China.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ying Du
- Employees
- 1,784
- Website
- www.zailaboratory.com
- Address
- Jinchuang Plaza, Shanghai, SH, 201210, CN
Zai Lab (ZLABN) Earnings & Revenues
ZLABN Company Deck
ZLABN Earnings Call
Earnings Call SentimentPositive
The call emphasized multiple near-term and medium-term positive catalysts: sequential revenue growth (11% QoQ to $105.8M), a commercially profitable business, a strong cash balance ($717.5M), rapid advancement of Zoci into global registrational trials with notable efficacy signals (38.2% ORR vs ~18% comparator in neuroendocrine carcinoma), and a busy pipeline with several upcoming data milestones (ESMO presentation, ZL-1503 healthy volunteer data H2 2026, ZL-6201 initial data H1 2027, ZL-1311 IND by year-end). Management also highlighted disciplined spending and productivity efforts. Counterbalancing these positives are supply constraints, near-term revenue timing issues related to NRDL and formulation transitions, increasing competition in the IL-13/IL-31 AD space, clinical safety/combination risks, and some ambiguity around the timing of profitability and key readouts. Overall, the positives — particularly pipeline momentum, commercial profitability, and cash runway — outweigh the operational and timing uncertainties.
View all MX:ZLABN earnings summariesZLABN Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 0 | 12 | 0 |
| Technical Analysis | 0 | 0 | 0 |
| Moving Averages | 0 | 12 | 0 |